TNG 908
Alternative Names: TNG-908Latest Information Update: 12 Jan 2024
At a glance
- Originator Tango Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023 2023)
- 07 Aug 2023 Pharmacokinetics data from phase I trial in Glioblastoma released by the Tango Therapeutics
- 09 May 2023 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by Tango Therapeutics